◆ 会议时间：2025年9月25-27日
◆ 会议地点：日本 石川县-金泽市

◆ 会议简介：

2025年第84届日本癌症协会(JCA)年会将于2025年9月25-27日在日本石川县金泽市举行，会议由日本癌症协会(JCA)主办。日本癌症协会(JCA)成立于1941年，其宗旨是通过主办年会及其他学术会议、出版刊物等宣促进癌症研究，JCA现拥有15000余名成员。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）.

第84回日本癌学会学術総会
The 84th Annual Meeting of the Japanese Cancer Association (JCA2024)

会期/Date:
2025年9月25日（木）〜27日（土）

会場/Venue:
石川県立音楽堂、ANAホテル、ホテル日航（予定）

Congress President:
大島正伸（金沢大学がん進展制御研究所　腫瘍遺伝学研究分野）

以下为往届会议信息，仅供参考！

摘要征文投稿：

点此提交摘要>>>Submit Abstract>>>

Welcome Message

The 83rd Annual Meeting of the Japan Cancer Association will be held at the Fukuoka International Conference Center from September 19th (Thursday) to 21st (Saturday), 2024. In recent years, the activities of academic conferences have been significantly impacted by Covid-19. Despite these challenges, the Japan Cancer Association has managed to maintain its vitality. Encouraged by the success of the 82nd Annual Meeting under the leadership of Chairman Mano, I am enthusiastically looking forward to the 83rd Annual Meeting, which promises to return to its original dynamic form.
The Japan Cancer Association takes pride in its long history and tradition. Its mission is to “explore the pathophysiology of cancer from the basics, collaborate between the fields of basic and clinical research, and disseminate new knowledge to the world, aiming to conquer cancer.” The fundamental understanding of cancer has rapidly advanced due to progress in measurement technologies in various omics fields such as genomics, epigenomics, proteomics, metabolomics, as well as innovations in information science and AI. Simultaneously, the development of numerous drugs, utilizing various modalities based on acquired information, to control cancer in clinical settings has also evolved rapidly. We are currently witnessing a significant transitional period from an era of cancer control to an era of complete cancer cure. Therefore, the theme for this meeting is simply “Cancer Research Aimed at Complete Cure.”
In Japan, the analysis of cancer-related gene sequences to optimize treatment methods, known as “cancer genomic medicine,” will commence in solid cancer areas from 2019 and extend to hematologic malignancies in 2024. Furthermore, new therapies not dependent on genetic mutations targeting cancer stem cells are also being developed. In the 83rd Annual Meeting, we aim to create a lively and vibrant academic conference where diverse individuals, including those involved in the development of measurement instruments and novel drugs, as well as healthcare professionals engaged in their clinical applications, gather under the mission of “eradicating cancer.” This conference in Fukuoka marks a return after nearly 20 years. Fukuoka is a charming city with excellent transportation accessibility. I sincerely hope that you actively participate on-site and enjoy the event. We look forward to your enthusiastic participation.

Koichi Akashi, M.D., Ph.D.
President, The 83rd Annual Meeting of the Japanese Cancer Association
Professor, Department of Medicine and Biosystemic Science,
Faculty of Medicine, Kyushu University

注册费：

Early Bird June 14, 2024 12:00 JST – July 22, 2024 23:59 JST
Regular Registration July 23, 2024 – October 31, 2024 23:59 JST

If you are the lead presenter of an open call or general abstract, please make sure to complete the admission procedure before the conference and register as a member status in advance.

For honorary members, we will send invitation individually, so there is no need to register online in advance.

◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。